Zimvie INC

ARCHIMED has completed its acquisition of ZimVie Inc., taking the global dental implant leader private at $19.00 per share.

ZimVie Inc. stockholders have overwhelmingly approved the acquisition of the company by an affiliate of ARCHIMED, paving the way for the merger to close on October 20, 2025.

ZimVie Inc. has filed supplemental disclosures to its merger proxy statement in response to stockholder litigation alleging material omissions, aiming to avoid delays in its acquisition by Zamboni Parent Inc.

ZimVie Inc. announced its second quarter 2025 financial results, showing improved profitability metrics, alongside the definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash, expected to close by year-end 2025.

ZimVie Inc., a global life sciences leader in the dental implant market, has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash, representing a significant premium for its stockholders.

ZimVie Inc. held its annual shareholder meeting on May 7, 2025, where shareholders elected a director, ratified the appointment of PricewaterhouseCoopers LLP as the company's auditor, and approved executive compensation on an advisory basis.

ZimVie Inc. has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash, representing a 99% premium, while reporting improved operating profit and reduced net loss for the second quarter and first half of 2025.

ZimVie Inc. reports a net loss of $1.471 million for Q1 2025, impacted by decreased sales and restructuring activities following the sale of its spine segment, while focusing on its dental business.

ZimVie Inc. reports a net loss of $2.284 million for the third quarter of 2024, following the sale of its spine segment.

ZimVie Inc. reports a net loss for the second quarter of 2024, impacted by the recent sale of its spine business, while focusing on its core dental operations.

ZimVie Inc. reports a net loss of $7.76 million for the first quarter of 2024, impacted by the divestiture of its spine business and restructuring activities.

ZimVie Inc. completes the sale of its spine segment and focuses on its dental business while navigating a challenging economic environment.

ZimVie Inc. reports a net loss for 2023, impacted by a significant write-down related to the sale of its spine business, while also highlighting growth in its dental segment.

ZimVie Inc.'s CFO, Richard Heppenstall, disposed of common stock and restricted stock units following the company's merger into a wholly-owned subsidiary of Zamboni Parent Inc. at $19.00 per share.

ZimVie Inc.'s President and CEO, Vafa Jamali, reported the disposal of all common stock and restricted stock units following the company's merger into a wholly-owned subsidiary.

Director Richard Kuntz's equity awards in ZimVie Inc. were converted to cash at $19.00 per share following the company's merger into a wholly-owned subsidiary.

ZimVie Inc. executive Heather Kidwell reported the disposition of common stock and restricted stock units following the company's merger into a wholly-owned subsidiary.

Indraneel Kanaglekar reports disposal of ZimVie shares and RSUs following the company's merger into a private entity.

ZimVie Inc. Director Sally Crawford disposed of all her common stock, deferred share units, and restricted stock units following the company's merger into a wholly-owned subsidiary.

ZimVie Inc. has provided frequently asked questions to employees regarding the proposed acquisition by an ARCHIMED affiliate, detailing voting procedures for shareholders.

ZimVie Inc. issues supplemental disclosures to its merger proxy amid stockholder lawsuits, reaffirms board's unanimous recommendation for Zamboni Parent acquisition.

ZimVie Inc. stockholders are invited to a special meeting on October 10, 2025, to vote on the proposed acquisition by ARCHIMED for $19.00 per share in cash.

ZimVie Inc. reported improved second-quarter 2025 financial results while confirming its definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash.

ZimVie Inc. announced its second quarter 2025 financial results will be reported on July 30, 2025, while reiterating its definitive agreement to be acquired by an ARCHIMED affiliate for $19.00 in cash per share, with the transaction expected to close by year-end 2025.

ZimVie Inc. has entered into a definitive agreement to be acquired by Zamboni Parent, Inc., an affiliate of ARCHIMED, a private equity firm focused on healthcare industries.

A group of investment entities led by Mario Gabelli has ceased beneficial ownership of ZimVie Inc. common stock following the completion of its acquisition by ARCHIMED.

A group of investment entities led by Mario Gabelli has disclosed a 5.02% beneficial ownership stake in ZimVie Inc., acquired for investment purposes totaling approximately $17.4 million.

J. Goldman & Co. LP, J. Goldman Capital Management, Inc., and Jay G. Goldman have filed an amended Schedule 13G, reporting zero beneficial ownership in ZimVie Inc. common stock.

Glazer Capital, LLC and Paul J. Glazer disclose beneficial ownership of 8.13% of ZimVie Inc.'s common stock in an amended Schedule 13G filing.

Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 7.07% of ZimVie Inc.'s common stock.

Camber Capital Management LP and Stephen DuBois report zero beneficial ownership in ZimVie Inc., signaling a complete exit from their previous stake.

Camber Capital Management LP and Stephen DuBois report beneficial ownership of 5.7% of ZimVie Inc.'s common stock, totaling 1.6 million shares.

Camber Capital Management LP and Stephen DuBois have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 6.8% of ZimVie Inc.'s common stock, totaling 1,885,000 shares as of March 31, 2025.